# SAE Capabilities Mapped to 6 Pillars of Cancer Intelligence

**Date:** January 28, 2025  
**Status:** âœ… **ACTIVE** - SAE capabilities mapped to 6 Pillars  
**Location:** `.cursor/MOAT/SAE_INTELLIGENCE/05_SAE_CAPABILITIES.md`  
**See Also:** [00_MISSION.mdc](00_MISSION.mdc) for mission overview, [03_GENERALS_BATTLE_MAP.mdc](03_GENERALS_BATTLE_MAP.mdc) for 6 Pillars framework

---

## ðŸ”— SAE CAPABILITIES â†’ 6 PILLARS MAPPING

### **PILLAR 1: TUMOR BURDEN** â†’ SAE Contribution

**What SAE Provides:**
- âœ… **CA-125 Intelligence Integration**
  - SAE resistance detection uses CA-125 trends (2-of-3 triggers)
  - CA-125 inadequate response (<50% drop by Cycle 3) â†’ resistance trigger
  - Baseline CA-125 tracked for resistance monitoring

**What's Missing:**
- âŒ Imaging-based tumor burden (CT/PET RECIST) - not integrated
- âŒ ctDNA tumor fraction tracking - partially built
- âŒ CTC count tracking - not built

**Connection Point:**
```
CA-125 Test â†’ SAE Resistance Detection â†’ Trigger System â†’ Actions
  â†“
Pattern: Rising after nadir â†’ Resistance signal
  â†“
Action: Order ctDNA, search trials, escalate to tumor board
```

---

### **PILLAR 2: GENOMIC EVOLUTION** â†’ SAE Contribution â­ **PRIMARY PILLAR**

**What SAE Provides:**
1. âœ… **DNA Repair Capacity** (Manager's C1 Formula)
   - Computes DNA repair capacity from mutations
   - Formula: `0.6Ã—DDR_pathway + 0.2Ã—HRR_essentiality + 0.2Ã—exon_disruption`
   - Example: BRCA1 biallelic â†’ DNA repair = 0.82 (HIGH)

2. âœ… **Pathway Burden** (7D Mechanism Vector)
   - Computes 7D mechanism vector: [DDR, MAPK, PI3K, VEGF, HER2, IO, Efflux]
   - Example: BRCA1 â†’ DDR=0.70, MAPK=0.10, others low

3. âœ… **Hotspot Detection** (COSMIC Database)
   - Detects KRAS/BRAF/NRAS hotspots
   - Maps to pathways (KRAS â†’ MAPK, BRAF â†’ MAPK)
   - Provides targeted therapy hints

4. âœ… **Resistance Detection** (2-of-3 Triggers)
   - HRD score drop â‰¥10 points vs baseline
   - DNA repair capacity drop â‰¥0.15 vs baseline
   - CA-125 inadequate response (<50% drop by Cycle 3)
   - Early resistance detection (3-6 weeks faster)

5. âœ… **Mechanism-Based Trial Matching**
   - Uses SAE mechanism vector for trial ranking
   - Cosine similarity: patient vector â†” trial MoA vector
   - Combined scoring: 0.7Ã—eligibility + 0.3Ã—mechanism_fit

**What's Missing:**
- âŒ ctDNA VAF tracking over time - partially built
- âŒ Clonal evolution detection - not built
- âŒ New mutation detection in ctDNA - not built

**Connection Point:**
```
ctDNA Test â†’ SAE Feature Service â†’ Mechanism Vector â†’ Trial Matching
  â†“
Pattern: New TP53 mutation + DDR pathway drop â†’ Resistance emerging
  â†“
Action: Re-rank drugs, search salvage trials, update care plan
```

---

### **PILLAR 3: IMMUNE STATUS** â†’ SAE Contribution

**What SAE Provides:**
- âœ… **IO Pathway in Mechanism Vector**
  - IO index in 7D mechanism vector: IO = 1.0 if TMB â‰¥20 OR MSI-High
  - IO-eligible patients get checkpoint inhibitors ranked higher
  - Mechanism fit for IO pathway in trial matching

**What's Missing:**
- âŒ PD-L1 expression tracking - not built
- âŒ TIL (tumor-infiltrating lymphocytes) analysis - not built
- âŒ Exhaustion markers (PD-1, TIM-3, LAG-3) - not built

**Connection Point:**
```
TMB Test â†’ SAE Mechanism Vector (IO index) â†’ Drug Efficacy â†’ Trial Matching
  â†“
Pattern: TMB â‰¥10 â†’ IO eligible
  â†“
Action: Boost checkpoint inhibitors in drug ranking, match IO trials
```

---

### **PILLAR 4: METABOLIC STATE** â†’ SAE Contribution

**What SAE Provides:**
- âŒ **Not Built Yet** - This is a new domain

**What Could Be Built:**
- PET-CT SUV max tracking (metabolic activity)
- Glucose/glutamine dependency analysis
- Lactate production tracking
- Metabolic pathway vulnerabilities (IDH mutations, etc.)

**Connection Point (Future):**
```
PET-CT Test â†’ Metabolic Analysis â†’ SAE Metabolic Features â†’ Drug Efficacy
  â†“
Pattern: High SUV despite stable size â†’ Metabolically active resistance
  â†“
Action: Consider metabolic inhibitors, escalate therapy
```

---

### **PILLAR 5: MICROENVIRONMENT** â†’ SAE Contribution

**What SAE Provides:**
- âŒ **Not Built Yet** - This is a new domain

**What Could Be Built:**
- Hypoxia markers (HIF-1Î±)
- Fibrosis markers (collagen, TGF-Î²)
- Treg/MDSC counts (suppressive immune cells)
- Angiogenesis markers (VEGF) - partially in mechanism vector

**Connection Point (Future):**
```
Microenvironment Test â†’ SAE Microenvironment Features â†’ Drug Efficacy
  â†“
Pattern: High VEGF + hypoxia â†’ Aggressive microenvironment
  â†“
Action: Consider bevacizumab, anti-angiogenic trials
```

---

### **PILLAR 6: TOXICITY/TOLERANCE** â†’ SAE Contribution

**What SAE Provides:**
- âš ï¸ **Indirect Contribution**
  - SAE doesn't directly compute toxicity, but:
  - Resistance detection can trigger dose adjustments
  - Pathway burden changes can indicate tolerance issues

**What's Missing:**
- âŒ Comprehensive toxicity tracking - partially built
- âŒ Dose adjustment recommendations - not built
- âŒ Supportive care recommendations - not built

**Connection Point:**
```
PGx Test â†’ Toxicity Risk â†’ SAE Resistance Detection â†’ Care Plan
  â†“
Pattern: DPYD variant detected â†’ 5-FU toxicity risk
  â†“
Action: Avoid 5-FU, suggest alternative, adjust dose
```

---

## ðŸ“Š SAE FEATURES BY PILLAR

| SAE Feature | Pillar(s) | Status | Impact |
|-------------|-----------|--------|--------|
| **DNA Repair Capacity** | Pillar 2 (Genomic Evolution) | âœ… Operational | HIGH - PARP sensitivity prediction |
| **Pathway Burden (7D)** | Pillar 2 (Genomic Evolution) | âœ… Operational | HIGH - Mechanism-based trial matching |
| **Hotspot Detection** | Pillar 2 (Genomic Evolution) | âœ… Operational | MEDIUM - Targeted therapy hints |
| **Resistance Detection** | Pillar 1 (Tumor Burden) + Pillar 2 (Genomic Evolution) | âœ… Operational | HIGH - Early resistance detection |
| **IO Pathway Index** | Pillar 3 (Immune Status) | âœ… Operational | MEDIUM - IO eligibility in mechanism vector |
| **VEGF Pathway** | Pillar 5 (Microenvironment) | âš ï¸ Partial | LOW - In mechanism vector, not fully utilized |

---

## ðŸŽ¯ STRATEGIC VALUE

### **SAE as Intelligence Source**

**For Pillar 2 (Genomic Evolution):**
- âœ… **Primary Intelligence Source** - SAE is the core capability
- âœ… **DNA Repair Capacity** - Predicts PARP sensitivity
- âœ… **Pathway Burden** - Guides mechanism-based matching
- âœ… **Resistance Detection** - Early warning system

**For Other Pillars:**
- âš ï¸ **Supporting Role** - SAE contributes but not primary
- âš ï¸ **Integration Points** - SAE features used by other systems
- âš ï¸ **Future Expansion** - Can add metabolic/microenvironment features

---

## ðŸ”— Related Files

**SAE System Debrief:**
- [01_SAE_SYSTEM_DEBRIEF.mdc](01_SAE_SYSTEM_DEBRIEF.mdc) - Complete debrief

**Strategic Framework:**
- [03_GENERALS_BATTLE_MAP.mdc](03_GENERALS_BATTLE_MAP.mdc) - 6 Pillars framework

**Intelligence Flow:**
- [04_INTELLIGENCE_FLOW.md](04_INTELLIGENCE_FLOW.md) - Test â†’ Signals â†’ Patterns â†’ Actions

---

*Document Owner: Zo*  
*Last Updated: January 28, 2025*  
*Status: âœ… ACTIVE - SAE capabilities mapped to 6 Pillars*


